1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Oncolytic Virus Cancer Immunotherapy Market Size Growth Rate by Type: 2018 VS 2022 VS 2032
1.2.2 Monoclonal Antibodies
1.2.3 Checkpoint Inhibitors
1.2.4 Oncoloytic Viral Therapies and Cancer Vaccines
1.3 Market by Application
1.3.1 Global Oncolytic Virus Cancer Immunotherapy Market Share by Application: 2018 VS 2022 VS 2032
1.3.2 Lung Cancer
1.3.3 Breast Cancer
1.3.4 Colorectal Cancer
1.3.5 Melanoma
1.3.6 Prostate Cancer
1.3.7 Head and neck Cancer
1.3.8 Ovarian Cancer
1.3.9 Pancreatic Cancer
1.3.10 Others
1.4 Study Objectives
1.5 Years Considered
2 Global Growth Trends
2.1 Global Oncolytic Virus Cancer Immunotherapy Market Perspective (2018-2032)
2.2 Oncolytic Virus Cancer Immunotherapy Growth Trends by Region
2.2.1 Oncolytic Virus Cancer Immunotherapy Market Size by Region: 2018 VS 2022 VS 2032
2.2.2 Oncolytic Virus Cancer Immunotherapy Historic Market Size by Region (2018-2023)
2.2.3 Oncolytic Virus Cancer Immunotherapy Forecasted Market Size by Region (2023-2032)
2.3 Oncolytic Virus Cancer Immunotherapy Market Dynamics
2.3.1 Oncolytic Virus Cancer Immunotherapy Industry Trends
2.3.2 Oncolytic Virus Cancer Immunotherapy Market Drivers
2.3.3 Oncolytic Virus Cancer Immunotherapy Market Challenges
2.3.4 Oncolytic Virus Cancer Immunotherapy Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Oncolytic Virus Cancer Immunotherapy Players by Revenue
3.1.1 Global Top Oncolytic Virus Cancer Immunotherapy Players by Revenue (2018-2023)
3.1.2 Global Oncolytic Virus Cancer Immunotherapy Revenue Market Share by Players (2018-2023)
3.2 Global Oncolytic Virus Cancer Immunotherapy Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Oncolytic Virus Cancer Immunotherapy Revenue
3.4 Global Oncolytic Virus Cancer Immunotherapy Market Concentration Ratio
3.4.1 Global Oncolytic Virus Cancer Immunotherapy Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Oncolytic Virus Cancer Immunotherapy Revenue in 2022
3.5 Oncolytic Virus Cancer Immunotherapy Key Players Head office and Area Served
3.6 Key Players Oncolytic Virus Cancer Immunotherapy Product Solution and Service
3.7 Date of Enter into Oncolytic Virus Cancer Immunotherapy Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Oncolytic Virus Cancer Immunotherapy Breakdown Data by Type
4.1 Global Oncolytic Virus Cancer Immunotherapy Historic Market Size by Type (2018-2023)
4.2 Global Oncolytic Virus Cancer Immunotherapy Forecasted Market Size by Type (2023-2032)
5 Oncolytic Virus Cancer Immunotherapy Breakdown Data by Application
5.1 Global Oncolytic Virus Cancer Immunotherapy Historic Market Size by Application (2018-2023)
5.2 Global Oncolytic Virus Cancer Immunotherapy Forecasted Market Size by Application (2023-2032)
6 North America
6.1 North America Oncolytic Virus Cancer Immunotherapy Market Size (2018-2032)
6.2 North America Oncolytic Virus Cancer Immunotherapy Market Size by Country (2018-2023)
6.3 North America Oncolytic Virus Cancer Immunotherapy Market Size by Country (2023-2032)
6.4 United States
6.5 Canada
7 Europe
7.1 Europe Oncolytic Virus Cancer Immunotherapy Market Size (2018-2032)
7.2 Europe Oncolytic Virus Cancer Immunotherapy Market Size by Country (2018-2023)
7.3 Europe Oncolytic Virus Cancer Immunotherapy Market Size by Country (2023-2032)
7.4 Germany
7.5 France
7.6 U.K.
7.7 Italy
7.8 Russia
7.9 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Oncolytic Virus Cancer Immunotherapy Market Size (2018-2032)
8.2 Asia-Pacific Oncolytic Virus Cancer Immunotherapy Market Size by Country (2018-2023)
8.3 Asia-Pacific Oncolytic Virus Cancer Immunotherapy Market Size by Country (2023-2032)
8.4 China
8.5 Japan
8.6 South Korea
8.7 Southeast Asia
8.8 India
8.9 Australia
9 Latin America
9.1 Latin America Oncolytic Virus Cancer Immunotherapy Market Size (2018-2032)
9.2 Latin America Oncolytic Virus Cancer Immunotherapy Market Size by Country (2018-2023)
9.3 Latin America Oncolytic Virus Cancer Immunotherapy Market Size by Country (2023-2032)
9.4 Mexico
9.5 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Oncolytic Virus Cancer Immunotherapy Market Size (2018-2032)
10.2 Middle East & Africa Oncolytic Virus Cancer Immunotherapy Market Size by Country (2018-2023)
10.3 Middle East & Africa Oncolytic Virus Cancer Immunotherapy Market Size by Country (2023-2032)
10.4 Turkey
10.5 Saudi Arabia
10.6 UAE
11 Key Players Profiles
11.1 AstraZeneca
11.1.1 AstraZeneca Company Detail
11.1.2 AstraZeneca Business Overview
11.1.3 AstraZeneca Oncolytic Virus Cancer Immunotherapy Introduction
11.1.4 AstraZeneca Revenue in Oncolytic Virus Cancer Immunotherapy Business (2018-2023)
11.1.5 AstraZeneca Recent Development
11.2 Amgen
11.2.1 Amgen Company Detail
11.2.2 Amgen Business Overview
11.2.3 Amgen Oncolytic Virus Cancer Immunotherapy Introduction
11.2.4 Amgen Revenue in Oncolytic Virus Cancer Immunotherapy Business (2018-2023)
11.2.5 Amgen Recent Development
11.3 F Hoffman-La Roche
11.3.1 F Hoffman-La Roche Company Detail
11.3.2 F Hoffman-La Roche Business Overview
11.3.3 F Hoffman-La Roche Oncolytic Virus Cancer Immunotherapy Introduction
11.3.4 F Hoffman-La Roche Revenue in Oncolytic Virus Cancer Immunotherapy Business (2018-2023)
11.3.5 F Hoffman-La Roche Recent Development
11.4 Bristol-Myers Squibb
11.4.1 Bristol-Myers Squibb Company Detail
11.4.2 Bristol-Myers Squibb Business Overview
11.4.3 Bristol-Myers Squibb Oncolytic Virus Cancer Immunotherapy Introduction
11.4.4 Bristol-Myers Squibb Revenue in Oncolytic Virus Cancer Immunotherapy Business (2018-2023)
11.4.5 Bristol-Myers Squibb Recent Development
11.5 Novartis AG
11.5.1 Novartis AG Company Detail
11.5.2 Novartis AG Business Overview
11.5.3 Novartis AG Oncolytic Virus Cancer Immunotherapy Introduction
11.5.4 Novartis AG Revenue in Oncolytic Virus Cancer Immunotherapy Business (2018-2023)
11.5.5 Novartis AG Recent Development
11.6 Merck & Co., Inc.
11.6.1 Merck & Co., Inc. Company Detail
11.6.2 Merck & Co., Inc. Business Overview
11.6.3 Merck & Co., Inc. Oncolytic Virus Cancer Immunotherapy Introduction
11.6.4 Merck & Co., Inc. Revenue in Oncolytic Virus Cancer Immunotherapy Business (2018-2023)
11.6.5 Merck & Co., Inc. Recent Development
11.7 Pfizer
11.7.1 Pfizer Company Detail
11.7.2 Pfizer Business Overview
11.7.3 Pfizer Oncolytic Virus Cancer Immunotherapy Introduction
11.7.4 Pfizer Revenue in Oncolytic Virus Cancer Immunotherapy Business (2018-2023)
11.7.5 Pfizer Recent Development
11.8 Biovex
11.8.1 Biovex Company Detail
11.8.2 Biovex Business Overview
11.8.3 Biovex Oncolytic Virus Cancer Immunotherapy Introduction
11.8.4 Biovex Revenue in Oncolytic Virus Cancer Immunotherapy Business (2018-2023)
11.8.5 Biovex Recent Development
11.9 Cell Genesys
11.9.1 Cell Genesys Company Detail
11.9.2 Cell Genesys Business Overview
11.9.3 Cell Genesys Oncolytic Virus Cancer Immunotherapy Introduction
11.9.4 Cell Genesys Revenue in Oncolytic Virus Cancer Immunotherapy Business (2018-2023)
11.9.5 Cell Genesys Recent Development
11.10 Crusade Laboratories
11.10.1 Crusade Laboratories Company Detail
11.10.2 Crusade Laboratories Business Overview
11.10.3 Crusade Laboratories Oncolytic Virus Cancer Immunotherapy Introduction
11.10.4 Crusade Laboratories Revenue in Oncolytic Virus Cancer Immunotherapy Business (2018-2023)
11.10.5 Crusade Laboratories Recent Development
11.11 Genelux Corporation
11.11.1 Genelux Corporation Company Detail
11.11.2 Genelux Corporation Business Overview
11.11.3 Genelux Corporation Oncolytic Virus Cancer Immunotherapy Introduction
11.11.4 Genelux Corporation Revenue in Oncolytic Virus Cancer Immunotherapy Business (2018-2023)
11.11.5 Genelux Corporation Recent Development
11.12 Lokon Pharma
11.12.1 Lokon Pharma Company Detail
11.12.2 Lokon Pharma Business Overview
11.12.3 Lokon Pharma Oncolytic Virus Cancer Immunotherapy Introduction
11.12.4 Lokon Pharma Revenue in Oncolytic Virus Cancer Immunotherapy Business (2018-2023)
11.12.5 Lokon Pharma Recent Development
11.13 MultiVir
11.13.1 MultiVir Company Detail
11.13.2 MultiVir Business Overview
11.13.3 MultiVir Oncolytic Virus Cancer Immunotherapy Introduction
11.13.4 MultiVir Revenue in Oncolytic Virus Cancer Immunotherapy Business (2018-2023)
11.13.5 MultiVir Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
